New drug combo aims to keep myeloma at bay longer
NCT ID NCT03004287
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests whether adding daratumumab, a newer multiple myeloma drug, to standard therapy helps people with newly diagnosed myeloma live longer without their cancer getting worse. About 50 participants will receive the drug as part of a total treatment plan. The goal is to improve progression-free survival, especially for those with high-risk disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Conditions
Explore the condition pages connected to this study.